AI Article Synopsis
- The implementation of a new integrated model of care for chronic hepatitis C virus (HCV) and multidrug- or rifampicin-resistant TB (MDR/RR-TB) in Armenia simplified treatment management and improved patient outcomes.
- Healthcare staff received training on HCV, enabling systematic testing and treating of patients receiving MDR/RR-TB therapy.
- Both staff and patients responded positively to the model, though staff requested more training while some patients expressed concerns about the increased number of pills.
Article Abstract
Background: Direct-acting antivirals (DAAs) are not widely used for patients with chronic hepatitis C virus (HCV) infection and multidrug- or rifampicin-resistant TB (MDR/RR-TB). We describe the implementation aspects of a new integrated model of care in Armenia and the perceptions of the healthcare staff and patients.
Methods: We used qualitative methods, including a desktop review and semi-structured individual interviews with healthcare staff and with patients receiving HCV and MDR/RR-TB treatment.
Results: The new integrated model resulted in simplified management of HCV and MDR/RR-TB at public TB facilities. Training on HCV was provided for TB clinic staff. All MDR/RR-TB patients were systematically offered HCV testing and those diagnosed with HCV, offered treatment with DAAs. Treatment monitoring was performed by TB staff in coordination with a hepatologist. The staff interviewed had a positive opinion of the new model. They suggested that additional training should be provided. Most patients were fully satisfied with the care received. Some were concerned about the increased pill burden.
Conclusion: Integrating HCV treatment into MDR/ RR-TB care was feasible and appreciated by patients and staff. This new model facilitated HCV diagnosis and treatment among people with MDR/RR-TB. Our results encourage piloting this model in other settings.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176196 | PMC |
| http://dx.doi.org/10.5588/pha.22.0002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Changing pathogenesis of liver cancer in Hawaii over three decades.
Cancer Epidemiol Biomarkers Prev
January 2025
Queen's Medical Center, Honolulu, HI, United States.
Background: Worldwide trends support the increasing contribution of hepatic steatosis on the incidence of hepatocellular carcinoma (HCC). This study investigates if similar changes are seen in Hawaii, where the incidence of HCC is higher than most of the United States. Methods; This is a retrospective study of 1651 patients diagnosed with HCC (1991-2023) that includes 60-70% of Hawaii's HCC cases.
View Article and Find Full Text PDFLong-Term Effects of Direct-Acting Antivirals on Hepatitis C: Trends in Liver Disease-Related Hospitalisations in Italy.
J Viral Hepat
February 2025
Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
This study aimed to evaluate the effectiveness of direct-acting antivirals (DAAs) on hepatitis C virus (HCV) hospitalisation trends in Italy, the country with not only the highest burden of HCV-related disease but also the highest number of patients treated for chronic HCV infection in Europe. Incident hospital discharge records in Italy from 2012 to 2019 that included a liver cirrhosis diagnosis without mention of alcohol, hepatocellular carcinoma (HCC), HCV and liver cirrhosis without mention of alcohol and/or HCC, cirrhosis with mention of alcohol, as defined by the International Classification of Diseases (ICD-9-CM) were reviewed. An interrupted time series analysis compared the incidence of cirrhosis and HCC before and after the introduction of DAAs (Year 2015).
View Article and Find Full Text PDFAssociation of MASLD Phenotypes With Liver Fibrosis in Hepatitis C: The Role of Cardiometabolic Risk Factors.
J Viral Hepat
February 2025
Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada.
Steatotic liver disease is prevalent among people with hepatitis C virus (HCV). The new definition of metabolic dysfunction-associated steatotic liver disease (MASLD) emphasises the metabolic drivers of steatosis and recognises its frequent coexistence with other chronic liver diseases, including HCV. We aimed to evaluate the association of coexisting MASLD and HCV with liver fibrosis.
View Article and Find Full Text PDFReply to: "Understanding virologic heterogeneity in chronic hepatitis B treatment".
JHEP Rep
February 2025
NIHR Health Informatics Collaborative, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Sociodemographic and clinical profiles of individuals with opioid dependence syndrome presenting to a tertiary care center in Assam: A retrospective review.
Indian J Psychiatry
December 2024
Department of Addiction Medicine, Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur, Assam, India.
Background: Opioid dependence is a critical public health issue in Northeast India, with limited data available on the affected population.
Aim: This study examines the sociodemographic and clinical profiles of opioid-dependent individuals in Assam.
Methods: A retrospective review was conducted of 238 patients diagnosed with opioid dependence at a tertiary care addiction treatment center in Assam, covering records from January 2022 to January 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!